Empower yourself with the knowledge and tools to navigate the complexities of drug-drug interactions in drug development successfully. In this webinar, you'll: ✔️ Learn to choose which interactions to examine when designing protocols ✔️ Acquire skills to interpret and analyze data from these trials ✔️ Explore real case studies from our Clinical Pharmacology Unit. Join expert Lotte Verwilligen in next week's webinar 👉 https://lnkd.in/eRYrxnMm #clinicalresearch #drugsafety #patientsafety
SGS Health Science’s Post
More Relevant Posts
-
Looking forward to our next webinar on clinical pharmacology!
Don't miss RRD's upcoming webinar on November 21st, "Optimizing NME and 505(b)(2) Programs: Lessons Learned in Clinical Pharmacology and Pharmacometrics," presented by Justus Bingham and Jen DiGiacinto. November 21st at 2:00 pm ET. Register here: https://lnkd.in/e44xcuJu What You’ll Gain: · Key takeaways from recent NME and 505(b)(2) programs · Insights on how to leverage your clinical pharmacology and pharmacometrics capabilities to ensure successful submissions · Strategies to use to avoid challenges unique to 505(b)(2) development Don’t miss the opportunity to learn about corrective measures taken to address actual issues during drug development programs that will equip you and your team with proven strategies!
To view or add a comment, sign in
-
Don't miss RRD's upcoming webinar on November 21st, "Optimizing NME and 505(b)(2) Programs: Lessons Learned in Clinical Pharmacology and Pharmacometrics," presented by Justus Bingham and Jen DiGiacinto. November 21st at 2:00 pm ET. Register here: https://lnkd.in/e44xcuJu What You’ll Gain: · Key takeaways from recent NME and 505(b)(2) programs · Insights on how to leverage your clinical pharmacology and pharmacometrics capabilities to ensure successful submissions · Strategies to use to avoid challenges unique to 505(b)(2) development Don’t miss the opportunity to learn about corrective measures taken to address actual issues during drug development programs that will equip you and your team with proven strategies!
To view or add a comment, sign in
-
Don't miss RRD's upcoming webinar on November 21st, "Optimizing NME and 505(b)(2) Programs: Lessons Learned in Clinical Pharmacology and Pharmacometrics," presented by Justus Bingham and Jen DiGiacinto. November 21st at 2:00 pm ET. Register here: https://lnkd.in/eDPmCzeY What You’ll Gain: · Key takeaways from recent NME and 505(b)(2) programs · Insights on how to leverage your clinical pharmacology and pharmacometrics capabilities to ensure successful submissions · Strategies to use to avoid challenges unique to 505(b)(2) development Don’t miss the opportunity to learn about corrective measures taken to address actual issues during drug development programs that will equip you and your team with proven strategies!
To view or add a comment, sign in
-
Check out what you missed in our latest webinar, The Basics of Drug-Drug Interaction Studies 📝 Expert tips on designing protocols 🔍 How to interpret results like a pro 💊 Everything you need to know about DDI trials 📚 Exclusive case study from SGS Clinical Pharmacology Unit Catch the full recording and level up your knowledge 👉 https://lnkd.in/eRYrxnMm #clinicalresearch #drugsafety #patientsafety
To view or add a comment, sign in
-
Two weeks today Altasciences will be hosting the symposium 'Current Trends for Efficient Drug Development' on Campus. Speakers include Robert Wilson, Drug Development and Clinical Pharmacology Director, at Healx who will share details of incorporating AI in drug discovery. Other topics will include regulatory pathways to conduct first-In-human trials in Canada and the journey of an obesity compound that has been 20 years in the making. Registration is essential - https://ow.ly/P69f50RFGlt
To view or add a comment, sign in
-
PharmaPro Consulting at the AAPS 2024 Pharm Sci 360! Join us from October 20-23, 2024, at the Salt Lake City Convention Center. Don't miss the opportunity to explore our poster presentation on “Gaps in Non-Binary Populations in Clinical Trial Participation: A Comparative Analysis of Cardiovascular and Solid Tumor Studies”, created in collaboration with FourFront. By Manu Datta and Patrick Valdivia. Connect with PharmaPro Consulting to discuss your Clinical Pharmacology, Pharmacometrics, and Regulatory needs, and with FourFront for your Data and Digital Marketing solutions. We look forward to seeing you there! #PharmSci360 #clinicalpharmacology #Pharmacometrics #Regulatory #Dataanalysis #FDA #RegulatoryAffairs #PharmaceuticalIndustry #LifeSciences #HealthcareInnovation #pharmaproconsulting
To view or add a comment, sign in
-
Here you go! Make sure you tune in and don't miss out! This webinar will discuss the final guidance for the industry on Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies which was published in July 2024. https://lnkd.in/ebEkMNHy
To view or add a comment, sign in
-
We had an incredible time hosting our recent webinar on "Clinical Pharmacology and Model-Informed Drug Development Insights for Targeted Radiation Therapies." If you couldn't make it, don't worry! Watch the webinar recording here: https://ow.ly/PQIf50SptKj 𝗪𝗵𝗮𝘁 𝗪𝗲 𝗖𝗼𝘃𝗲𝗿𝗲𝗱: 🔍 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗼𝗹𝗼𝗴𝘆: What is the regulatory landscape for targeted radiation therapies (TRTs) and what clin pharm studies are required. 🧬 𝗠𝗼𝗱𝗲𝗹𝗶𝗻𝗴 𝗮𝗻𝗱 𝗦𝗶𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻: How quantitative systems pharmacology and pharmacometrics can inform your TRT program For additional insights, check out our website (https://ow.ly/lINk50SptKg) or latest blog post (https://ow.ly/zPCT50SptKh) on the importance of Clinical Pharmacology and Modeling & Simulation in TRT success. See you at our next webinar! #WebinarRecap #ClinicalPharmacology #DrugDevelopment #TRT #ModelingAndSimulation #WebinarRecording
To view or add a comment, sign in
-
Happy to share that I have successfully completed the course on Principles of Clinical Pharmacology at NIH! Excited to apply this invaluable knowledge to advancing healthcare and drug development. #ClinicalPharmacology #NIH #HealthcareAdvancement"
To view or add a comment, sign in
-
In the second installment of our #ADC Blog Series, we address the #FDA's current guidance on the clinical pharmacology considerations of ADCs and what it means for companies and patients. Check out the article and the entire blog series below. #pharma
Cancer Drugs (Antibody Drug Conjugates): An FDA Perspective | Foley & Lardner LLP
To view or add a comment, sign in
19,710 followers